Syndax Pharmaceuticals (SNDX) Cash from Operations (2015 - 2026)

Syndax Pharmaceuticals' Cash from Operations history runs 12 years deep, the most recent figure standing at 50345000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 47.1% year-over-year to 50345000.0 in Q1 2026; TTM through Mar 2026 was 278163000.0, a 2.92% increase from a year earlier, with the FY2025 full-year figure at 322980000.0, down 17.49% from the prior year.
• Cash from Operations rose to 50345000.0 in Q1 2026 per SNDX's latest filing, from 69488000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 22894000.0 in Q4 2022 and bottomed at 95162000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 50345000.0 (2026), against an average of 55441411.76.
• Across the five-year window, Cash from Operations tumbled 122.73% in 2022 and surged 47.1% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 22894000.0 in 2022, then slumped by 80.61% to 41349000.0 in 2023, then plunged by 38.79% to 57388000.0 in 2024, then decreased by 21.08% to 69488000.0 in 2025, then advanced by 27.55% to 50345000.0 in 2026.
• Per Business Quant, the three latest SNDX Cash from Operations figures stand at 50345000.0 (Q1 2026), 69488000.0 (Q4 2025), and 70535000.0 (Q3 2025).